Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 4Active not recruiting 2Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Neoplasms 2Solid Tumors 1Multiple Endocrine Neoplasia Type 2a 1Lung Neoplasms 1Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 1

Interventions

pembrolizumab 26Cyclophosphamide 20Nivolumab 14Doxorubicin 13Surveys and Questionnaires 9Exercise 9Carboplatin 9atezolizumab 8Vincristine 8Rituximab 8Radiotherapy 8Prednisone 8Paclitaxel 8Dexamethasone 8Bevacizumab 8venetoclax 7fludarabine 7Fluorouracil 7Docetaxel 7Blood Specimen Collection 7lenvatinib 6dostarlimab 6cemiplimab 6budigalimab 6Pemetrexed 6Oxaliplatin 6Cisplatin 6durvalumab 5Leucovorin 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms × alectinib × Clear all
NCT03194893 2026-05-20

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Hoffmann-La Roche

Phase 3 Active not recruiting
200 enrolled
EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Multiple Endocrine Neoplasia Type 2a

NCT03768063 2026-04-28

IMbrella B

Hoffmann-La Roche

Phase 3 Active not recruiting
1,000 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡